相关实验视频

Updated: Sep 11, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

开发Zongertinib治疗HER2突变NSCLC的方法

Danielle Brazel¹, Cathleen J Park², Misako Nagasaka³

¹Scripps Clinic/Scripps Green Hospital, Department of Hematology/Oncology, 10166 N Torrey Pines Rd., La Jolla, CA 92037, United States.

Critical reviews in oncology/hematology

|August 15, 2025

概括

格丁尼布在治疗HER2突变非小细胞肺癌 (NSCLC) 方面表现有前途,这是该疾病的罕见和侵袭性形式. 这种新疗法提供了希望,特别是对于脑转移患者来说,解决了重要的未满足需求.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

人类表皮生长因子受体2 (HER2) 突变在非小细胞肺癌 (NSCLC) 中不常见.
从历史上看,HER2突变NSCLC的预后较差,临床需求未得到满足,近50%的患者被诊断患有大脑转移.
现有的治疗方法,如trastuzumab deruxtecan,仅限于二线设置.

研究的目的:

评估Zongertinib的疗效和安全性,Zongertinib是一种新的HER2选择性氨酸激酶抑制剂,在患有HER2突变NSCLC的患者中使用.
评估Zongertinib在治疗脑转移的NSCLC方面的潜力,因为它具有穿透血脑屏障的能力.
报告从临床前研究和I期Beamion LUNG-1试验中获得的支持Zongertinib临床开发的结果.

主要方法:

临床前研究评估Zongertinib的作用机制和体外/体内活性.
第I阶段Beamion LUNG-1临床试验,评估Zongertinib在患有HER2突变NSCLC的患者中的安全性,耐受性和初步疗效.
对试验参与者的反应率和安全概况的分析.

主要成果:

格丁尼布证明了对HER2受体的共价结合,包括具有exon20ins突变的受体.
临床前研究和Beamion LUNG-1试验的初步结果显示出有希望的反应率和有利的安全性.
这些发现支持了随后的FDA加速批准Zongertinib于2025年8月8日.

结论:

格丁尼布在治疗HER2突变NSCLC方面取得了重大进展.
它的有效性和安全性概况表明它是一种有价值的治疗选择,特别是在脑转移患者中.
该药物解决了NSCLC患者的一个具有挑战性的子集的关键未满足需求.

关键词:

在ERBB2中,它是ERBB2.人类表皮生长因子受体2 人类表皮生长因子受体2 有针对性的治疗.铁氨酸激酶抑制剂铁氨酸激酶抑制剂血脑屏障的透血脑屏障的透

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...